Deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program. (2022). SKIN The Journal of Cutaneous Medicine, 6(6), s48. https://doi.org/10.25251/skin.6.supp.48